Mallia Therapeutics GmbH
Mallia Therapeutics GmbH is a biopharmaceutical company focused on developing novel treatments for patients suffering from hair loss. Hormone-induced male or female pattern hair loss (androgenetic alopecia) affects over half of all men and many women. Mallia Therapeutics aims to enter the multi-billion-dollar alopecia market by offering patients a safe and effective topical therapy based on the human soluble protein sCD83. Promising preclinical data show that the immunomodulator sCD83 stimulates both hair growth and new hair follicle formation via a dual mechanism of action with no evidence of the side effects common for systemic treatments. Thus, sCD83 should offer distinct advantages over marketed treatments. The Company is led by an experienced management team and worldwide leading experts in the field of CD83 biology.
About Mallia Therapeutics GmbH:
| Field of Activity | Mallia Therapeutics develops sCD83 for the treatment of hormone-induced male or female pattern baldness (= androgenetic alopecia) and autoimmune mediated male or female patchy hair loss (= alopecia areata), the two most prevalent forms of hair loss. |
| Ownership Structure and Financing | Private company; seed funding secured, and Series A planned to finance clinical development |
| Technology | sCD83 is a human derived protein that induces new hair growth when applied topically. In preclinical in vivo models, it induces an anti-inflammatory milieu and thereby promotes hair growth. In addition, sCD83 directly binds to human hair follicles to activate hair follicle stem cells and thus inducing new hair growth. |
| USP | sCD83 can be applied topically to activate the hair follicle, which is a big advantage compared to systemic treatment options. Unlike other topical treatments, it not only accelerates hair growth, but also induces the formation of new hair follicles. |
Contact:
| Address | Mallia Therapeutics GmbH Henkestr. 91 91052 Erlangen, Germany |
| info@mallia-therapeutics.com | |
| Web Address | https://mallia-therapeutics.com/ |
| Social Media | |
| Date of Incorporation/Number of Employees | 2023/3 |
- Biotech und Life Sciences von Norden bis Süden
- Formycon: „Spurwechsel zum Unternehmen mit kommerziell erfolgreichen Produkten“
- It's time to focus on cardiovascular diseases!
- Case Study mbiomics: Labora et Darmflora
- „Das IZB ist das Global Village für Biotechnologie in Deutschland“
- Medikamentenentwicklung: Effizienzsteigerung durch spezialisierte Plattformen?
- Agile Transformation der digitalen Produktentwicklung
- MAxL in Martinsried: BioM eröffnet neuen Start-up-Inkubator
- Pharma fängt Beschäftigungsverluste auf
- Molecular Health und Integrated DNA Technologies vereinbaren kommerzielle Partnerschaft
- Case Study Invitris GmbH: Phagenkompetenz gegen Antibiotikaresistenz
- „What’s the deal“ in Smarter Medizin, Nachhaltigkeit und Finanzierung?
- Chemieumsatz geht leicht zurück
- Eli Lilly und Novo Nordisk: Pharmariesen gewinnen an Gewicht
- Bertelsmann Investments erwirbt Pharma-Tech-Unternehmen EXTEDO
- Cicor: Übernahme der STS Defence Limited abgeschlossen
- Helix BioPharma: Mit basischem Milieu gegen Krebszellen
- Lilly plant 2,5-Mrd.-USD-Standort im rheinland-pfälzischen Alzey
- The potential of AI in drug discovery
- „Es herrscht ein regelrechter Hype um diesen Markt“